Breakthrough Parkinson’s tech to help 150,000 Brits in 2023

There could be a “paradigm shift” in the treatment of Parkinson’s disease, with breakthrough tech set to help 150,000 UK citizens in 2023. 

Thousands of people with Parkinson’s Disease may soon benefit from “breakthrough” technology which experts claim could lead to a “paradigm” shift in treatment. 

NICE, the National Institute for Health and Care Excellence, is currently evaluating a continuous monitoring system for people with Parkinson’s known as PDMonitor. Created by medical device company PD Neurotechnology, the new technology could be used by the NHS as soon as next year. 

It’s expected that PD Neurotechnology will submit information to NICE before a Committee meeting set for next summer. It’s at this meeting where the devices for remote continuous monitoring of people with Parkinson’s disease will be discussed. 

NICE’s Diagnostic Assessment Programme is evaluating four medical devices – PDMonitor being just one of them.  

Parkinson’s treatment technology

The company uses medical-grade wearable technology to track Parkinson’s motor symptoms automatically and on an ongoing basis. It enables physicians to tailor treatment plans based on a stream of objective data showing how patients experience symptoms in their day-to-day lives.

More than 150 physicians have already been trained to use PDMonitor, and

The technology is currently used in private or hospital practice by physicians and patients in the UK, as well as parts of Europe such as France, Austria, Germany, Italy, Spain, Sweden, Ireland, Greece and Cyprus. Over 150 physicians have already been trained to use PDMonitor.

A “paradigm” shift for Parkinson’s disease

Professor Ray Chaudhuri, Head of Parkinson’s Research at King’s College Hospital, who has been piloting PDMonitor with private patients since March 2022, comments: “Parkinson’s is the world’s second most common neurodegenerative disease and a significant cause of disability.

“Patients’ quality of life and disease progression strongly depend on the consistent, prompt staging of the disease and optimal timing and dosing of the prescribed therapy.”

“PDMonitor is supporting a paradigm shift in Parkinson’s care by improving the quality and timeliness of information physicians have to assess the disease.

“Monitoring patients at home, continuously while they conduct everyday activities, allows treatment decisions to be made more frequently and physicians to respond faster to changing symptoms.

“While you cannot reverse Parkinson’s, you can delay the deterioration of symptoms and possibly decrease the risk of falling. Optimising care means the disease progresses slower in time and the therapeutic window is kept open.”

Transformative, medical-grade technology

Nikos Moschos, founder of PD Neurotechnology said: “Today, most Parkinson’s treatment is informed by subjective patient diaries reviewed by physicians once or twice a year. We’ve changed the game by providing physicians with a stream of objective data showing disease progression in the real world.”

“Our transformative, medical-grade technology offers continuous monitoring, full symptom coverage and a holistic view of the patient. The majority of patients feel their health and quality of life stabilised or improved after using PDMonitor. This is data and AI at its finest.”

Don’t miss…

How AI will disrupt the treatment of Parkinson’s